A Randomized, Placebo-Controlled, Double Blind, Multicenter Phase 2 Study to Explore Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Multiple Infusions of NI-0101, an anti-Toll Like Receptor 4 Monoclonal Antibody in Patients with Rheumatoid Arthritis
Phase of Trial: Phase II
Latest Information Update: 17 Nov 2017
At a glance
- Drugs NI 0101 (Primary)
- Indications Rheumatoid nodule
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept; Therapeutic Use
- Sponsors NovImmune SA
- 17 May 2017 Status changed from planning to recruiting.
- 15 Dec 2016 New trial record
- 05 Dec 2016 According to a Novimmune media release, under the terms of the agreement, Genentech receives an exclusive option to license all rights to develop and commercialize NI-0101, pending the results of this study.